Last reviewed · How we verify
Ursolvan — Competitive Intelligence Brief
phase 3
Aldo-keto reductase family 1 member C2, CDGSH iron-sulfur domain-containing protein 1, Ectonucleotide pyrophosphatase/phosphodiesterase family member 2
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Ursolvan (Ursolvan) — Hopital Foch.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ursolvan TARGET | Ursolvan | Hopital Foch | phase 3 | Aldo-keto reductase family 1 member C2, CDGSH iron-sulfur domain-containing protein 1, Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Ursolvan — Competitive Intelligence Brief. https://druglandscape.com/ci/ursolvan. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing